NuCana Announces Update for Phase 3 Biliary Tract Cancer Study
March 02, 2022 16:01 ET
|
NuCana plc
Independent Data Monitoring Committee Recommended Study be Discontinued Following Futility Assessment Conducted at First Interim Analysis NUC-3373 Continues Rapid Development with Multiple Data...
NuCana to Participate in Two Upcoming Investor Conferences
February 28, 2022 16:01 ET
|
NuCana plc
EDINBURGH, United Kingdom, Feb. 28, 2022 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will...
NuCana Announces Enrollment of Required Number of Patients to Conduct Second Interim Analysis in the Phase III Biliary Tract Cancer Study
February 22, 2022 16:01 ET
|
NuCana plc
Enrollment of 644 Evaluable Patients Expected to Enable Second Interim Analysis in the Second Half of 2022 First Interim Analysis of 418 Evaluable Patients Remains on Track for the First Half of 2022...
NuCana Reports Third Quarter 2021 Financial Results and Provides Business Update
November 18, 2021 16:01 ET
|
NuCana plc
Enrolled Required Number of Patients to Conduct First Interim Analysis in Phase 3 Biliary Tract Cancer Study in the First Half of 2022 Received Fast Track Designation from FDA for Acelarin for...
NuCana to Present at the Jefferies 2021 London Healthcare Conference
November 10, 2021 08:00 ET
|
NuCana plc
EDINBURGH, United Kingdom, Nov. 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will...
NuCana Appoints Elliott M. Levy, M.D. to its Board of Directors
November 01, 2021 16:01 ET
|
NuCana plc
EDINBURGH, United Kingdom, Nov. 01, 2021 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients...
NuCana Receives Fast Track Designation from the U.S. Food and Drug Administration for Acelarin® (NUC-1031) for the Treatment of Biliary Tract Cancer
September 29, 2021 08:00 ET
|
NuCana plc
EDINBURGH, United Kingdom, Sept. 29, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Acelarin...
NuCana Announces Four Poster Presentations at the ESMO Congress 2021
September 16, 2021 08:00 ET
|
NuCana plc
NUC-3373 Continues to Demonstrate Encouraging Efficacy Signals and a Favorable Safety Profile in Patients with Advanced Colorectal Cancer NUC-3373 Phase 1 Study Demonstrated Encouraging...
NuCana Announces Enrollment of Required Number of Patients to Conduct First Interim Analysis in the Phase III Biliary Tract Cancer Study
September 15, 2021 08:00 ET
|
NuCana plc
Enrollment of 418 Evaluable Patients Expected to Enable First Interim Analysis in the First Half of 2022 Data from First Interim Analysis May Support an NDA Submission in the United States under the...
NuCana to Participate in Three Upcoming Investor Conferences
September 01, 2021 08:00 ET
|
NuCana plc
EDINBURGH, United Kingdom, Sept. 01, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will...